The T-RRex study is testing a new treatment called WU-CART-007 for people with a type of blood cancer known as T-Cell Acute Lymphoblastic Leukemia (T-ALL) or Lymphoblastic Lymphoma (LBL). These cancers affect the blood and immune system. The study is in Phase 2, which means it's looking at how well the treatment works. Patients in this study have cancer that has come back or hasn't responded to other treatments. The goal is to see if WU-CART-007 can help make the cancer undetectable, known as Minimum Residual Disease (MRD) negative.

• The study is open to patients 6 months and older, in good health with specific types of blood cancer.
• Participants cannot have had previous anti-CD7 therapy or certain health conditions.
• This is a single-arm study, meaning all participants receive the same treatment.

If you join, you will receive the treatment and be monitored by doctors at various locations to check its effectiveness.